Triple-negative breast cancer: an update on neoadjuvant clinical trials (Q35725961)

9 August 2017

title

Triple-negative breast cancer: an update on neoadjuvant clinical trials (English)

1 reference

triple-negative breast cancer

9 August 2017

main subject

1 reference

Keith D Amos

1

1 reference

9 August 2017

Barbara Adamo

series ordinal

2

1 reference

9 August 2017

Carey K Anders

series ordinal

3

1 reference

9 August 2017

publication date

24 January 2012

1 reference

International Journal of Breast Cancer

9 August 2017

published in

1 reference

9 August 2017

volume

2012

1 reference

9 August 2017

page(s)

385978

1 reference

Creative Commons Attribution 3.0 Unported

9 August 2017

copyright license

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Surgical issues and preoperative systemic therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Molecular portraits of human breast tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

A new approach to the management of primary unresectable carcinoma of the breast: is radiation therapy necessary?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

What Is the Evidence That Tumors Are Angiogenesis Dependent?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

12 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F385978

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3270519

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22461984

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22461984

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22461984

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2012/385978

1 reference

9 August 2017

1 reference

9 August 2017

1 reference